Bezuclastinib

Name: Bezuclastinib in Nonadvanced systemic mastocytosis: Pathophysiology
Published: 2026-09-14T15:39:06-04:00

Nonadvanced systemic mastocytosis

Manufacturer: Cogent Biosciences
Regulatory submission: NDA submitted December 2025
Launch: Anticipated in the second half of 2026
Last updated: September 17, 2026

Section

Product information and disease description Place of product in therapy Disease description

Pathophysiology

1 evidence topic · 1 source

Pathophysiology

“KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells.” (opens the source at this quote in a new tab)